

Low glycaemic index diet for type 2 diabetics

Submission date 13/01/2010	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 18/01/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 28/05/2019	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Type 2 diabetes is a condition where the pancreas doesn't produce enough insulin or the body's cells don't react to insulin, causing the blood sugar level to become too high. The aim of this study is to determine how the type of foods in a diet can affect blood sugar control and heart and blood vessel health in people with type 2 diabetes. The glycaemic index is a scale that ranks carbohydrate foods by how much they raise blood sugar levels compared to a standard food. In this study a low glycaemic index diet is compared to a standard healthy high fibre diet.

Who can participate?

Patients aged over 21 with type 2 diabetes

What does the study involve?

Participants are randomly allocated to be given dietary advice on either a low glycaemic index diet or a high fibre diet. They are required to keep a 7-day food record every 3 months throughout the 3-year study. Blood tests and body measurements are carried out every 3 months. Participants undergo MRI and ultrasound scans to look at the walls of the carotid arteries, the largest blood vessels in the neck. Retinal photographs are taken to look at the arteries in the eye. The MRI, ultrasound, and eye tests are done at the beginning of the study, after 1 year, and at the end (3 years).

What are the possible benefits and risks of participating?

This study assesses whether this dietary help can improve risk factors for heart disease. This may not benefit participants, but may improve how patients are treated in the future. There are small risks with having blood drawn and if a contrast dye is used for the MRI, which are explained in the consent form.

Where is the study run from?

1. St Michael's Hospital (Canada)
2. University of Toronto (Canada)

When is the study starting and how long is it expected to run for?

February 2010 to August 2016

Who is funding the study?
Canadian Institutes of Health Research (Canada)

Who is the main contact?
Dr David Jenkins

Contact information

Type(s)
Scientific

Contact name
Dr David Jenkins

Contact details
61 Queen St. East, 6th Floor
Toronto
Canada
M5C 2T2

Additional identifiers

ClinicalTrials.gov (NCT)
NCT01063374

Protocol serial number
09-193; MCT-98825

Study information

Scientific Title
Low glycaemic index diets to improve glycaemic control and cardiovascular disease in type 2 diabetics: a randomised controlled trial

Study objectives
A low glycaemic index diet will improve glycaemic control and plaque build-up in type 2 diabetics, compared to a high fibre diet.

Ethics approval required
Old ethics approval format

Ethics approval(s)
St Michael's Hospital Research Ethics Board, 16/12/2009, ref: REB09-093

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Type 2 diabetes

Interventions

Participants will be randomly assigned to receive dietary counselling for either a low glycaemic index diet, or a high cereal fibre diet for a three year period. Subjects will be followed for 3 years after starting the study.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Current primary outcome measures as of 15/09/2016:

Plaque volume, assessed by MRI at 1 and 3 years

Previous primary outcome measures:

1. Carotid intima media thickness
2. HbA1c
3. Plasma glucose and lipids

Magnetic resonance imaging (MRI) of intima media will take place at 0, 1 year, and 3 years. Blood tests and clinic visits will take place every 3 months during the 3 years.

Key secondary outcome(s)

Current secondary outcome measures as of 15/09/2016:

1. Intima media thickness, assessed by 3D carotid ultrasound at 1 and 3 years
2. Plaque morphology measured at 1 and 3 years
3. HbA1c measured every 3 months for 3 years
4. Serum lipids measured every 3 months for 3 years
5. Blood pressure measured every 3 months for 3 years
6. Serum fasting glucose measured every 3 months for 3 years
7. Creatinine, urea, and C-peptides in 24 hour urine collection measured at 1 and 3 years
8. Anthropometric measures (weight, waist and hip circumference), measured every 3 months for 3 years
9. Retinal photography measured at 1 and 3 years

Previous secondary outcome measures:

1. Anthropometric measures
2. Blood and urine tests

Blood tests and clinic visits will take place every 3 months during the 3 years.

Completion date

01/08/2016

Eligibility

Key inclusion criteria

Current inclusion criteria as of 15/09/2016:

1. Type 2 diabetes diagnosed for greater than 6 months
2. Men and women aged over 21 years
3. Stable dose of hypoglycaemic medication
4. HbA1c between 6.5 and 8.0 at screening, and pre-study visit
5. Stable weight
6. Family physician and valid health card
7. Stable dose of lipid medication, if prescribed
8. Stable dose of blood pressure medication, if prescribed
9. Ability to keep written food records, use digital food scale

Previous inclusion criteria:

1. Type 2 diabetes diagnosed for greater than 6 months
2. Men and post-menopausal women, aged over 21 years
3. Stable dose of hypoglycaemic medication
4. HbA1c between 6.5 and 8%
5. Stable weight
6. Family physician and valid health card
7. Stable dose of lipid medication, if prescribed
8. Stable dose of blood pressure medication, if prescribed
9. Ability to keep written food records, use digital food scale

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Insulin, steroids, or warfarin
2. Gastrointestinal disease
3. Major cardiovascular event in past 6 months
4. Major surgery in past 6 months
5. Liver disease, hepatitis B or C
6. Renal failure
7. Major debilitating disorder
8. Serum triglycerides greater than 6 mmol/L
9. History of cancer (except non-melanoma skin cancer)
10. Pre-menopausal women
11. Food allergies to study foods
12. Blood pressure above 145/90 mmHg
13. Acute or chronic infections

14. Chronic inflammatory diseases
15. Inability to undergo magnetic resonance imaging (MRI)
16. Any other condition which make one unsuitable for the study

Date of first enrolment

01/02/2010

Date of final enrolment

01/05/2013

Locations

Countries of recruitment

Canada

Study participating centre**St Michael's Hospital**

Toronto

Canada

M5C 2T2

Sponsor information

Organisation

St Michael's Hospital (Canada)

Organisation

University of Toronto (Canada)

Organisation

St. Michael's Hospital

ROR

<https://ror.org/04skqfp25>

Funder(s)

Funder type

Research organisation

Funder Name

Canadian Institutes of Health Research (ref: MCT-98825)

Alternative Name(s)

Instituts de Recherche en Santé du Canada, The Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research (CIHR), Canadian Institutes of Health Research | Ottawa ON, CIHR - Welcome to the Canadian Institutes of Health Research, CIHR, IRSC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

Canada

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary****Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	07/07/2016		Yes	No
Interim results article	baseline data	22/03/2017		Yes	No